Pharmaceutical & Biotech Licensing Strategies - Driving Revenue through Partnerships
出 版 商：CBR Pharma Insights
出版日期：2011/01/15
頁 數：55頁
文件格式：PDF
價 格：
USD 3,900 (Single-User License)
USD 4,900 (Multi-User License)
USD 9,800 (Global-User License)
USD 4,900 (Multi-User License)
USD 9,800 (Global-User License)
Pharmaceutical & Biotech Licensing Strategies - Driving Revenue through Partnerships
Summary
In today’s pharmaceutical industry, multiple factors – looming patent expirations, depleted pipelines, increases in R&D expenditures, payer pressures, and tighter FDA regulations- have forced Big Pharma to change its business model. The evolving model is one grounded in collaboration. Companies are no longer relying solely on their own internal R&D programs for innovation; they are looking outside of their four walls. Some have labeled this ‘search and development’.
There are many types of alliances that support this collaborative model. One type, in-licensing products, is very appealing. The number of licensing agreements has grown year over year since 2007. The top companies are interested in several key therapeutic areas including oncology, CNS, and infectious disease. These companies are also more focused on products in the early phases of development.
This consultancy-style report focuses on licensing activity in 2010, the trends that we’re seeing in the changing pharmaceutical environment, and the motivations for companies – on both sides – to do deals in recent years.
Scope
- Licensing deal trends by deal activity, therapeutic area, stage of development and value
- Analysis of key players
- Review of rationale behind in-licensing and out-licensing deal trends
Reasons to buy
- Gain access to a fully sourced, executive assessment of the trends within pharmaceutical & biotech licensing activity and how those trends support company growth
- Identify who the leading companies are from an in-license & out-license point of view and if they are keeping to their overall corporate strategy
- Benefit from CBR’s case study analysis which supports the various motivations companies have to engage in licensing activity
- Understand the key issues driving the changes that are being seen within the pharmaceutical industry and why new business models are evolving to support continued revenue growth
Summary
In today’s pharmaceutical industry, multiple factors – looming patent expirations, depleted pipelines, increases in R&D expenditures, payer pressures, and tighter FDA regulations- have forced Big Pharma to change its business model. The evolving model is one grounded in collaboration. Companies are no longer relying solely on their own internal R&D programs for innovation; they are looking outside of their four walls. Some have labeled this ‘search and development’.
There are many types of alliances that support this collaborative model. One type, in-licensing products, is very appealing. The number of licensing agreements has grown year over year since 2007. The top companies are interested in several key therapeutic areas including oncology, CNS, and infectious disease. These companies are also more focused on products in the early phases of development.
This consultancy-style report focuses on licensing activity in 2010, the trends that we’re seeing in the changing pharmaceutical environment, and the motivations for companies – on both sides – to do deals in recent years.
Scope
- Licensing deal trends by deal activity, therapeutic area, stage of development and value
- Analysis of key players
- Review of rationale behind in-licensing and out-licensing deal trends
Reasons to buy
- Gain access to a fully sourced, executive assessment of the trends within pharmaceutical & biotech licensing activity and how those trends support company growth
- Identify who the leading companies are from an in-license & out-license point of view and if they are keeping to their overall corporate strategy
- Benefit from CBR’s case study analysis which supports the various motivations companies have to engage in licensing activity
- Understand the key issues driving the changes that are being seen within the pharmaceutical industry and why new business models are evolving to support continued revenue growth
Executive Summary
Introduction
The Pharmaceutical business model is changing
Alliances supporting a collaborative model
Licensing Deal Trends
Annual deal activity
Leading therapeutic areas
Level of activity by stage of development
Value of licensing deals
Players in the Licensing Game
Active players in 2010
Are licensing activities aligned with overall corporate strategy?
Strategic Motivations Behind Licensing Activity – A case study analysis
In-licensing
Offset patent expiration or bolster research efforts
Transition from blockbuster to niche buster
Expansion and diversification
Improve and speed up the R&D process
Strategic Motivations Behind Licensing Activity – A case study analysis (continued)
Out-licensing
Funding to continue current and future R&D projects
Establish commercial capabilities or expand on current ones
Appendix
Introduction
The Pharmaceutical business model is changing
Alliances supporting a collaborative model
Licensing Deal Trends
Annual deal activity
Leading therapeutic areas
Level of activity by stage of development
Value of licensing deals
Players in the Licensing Game
Active players in 2010
Are licensing activities aligned with overall corporate strategy?
Strategic Motivations Behind Licensing Activity – A case study analysis
In-licensing
Offset patent expiration or bolster research efforts
Transition from blockbuster to niche buster
Expansion and diversification
Improve and speed up the R&D process
Strategic Motivations Behind Licensing Activity – A case study analysis (continued)
Out-licensing
Funding to continue current and future R&D projects
Establish commercial capabilities or expand on current ones
Appendix
